Sisyphus and 30-day heart failure readmissions. Futility in predicting a flawed outcome metric

JACC: Heart Failure

Volumn 4, Issue 1, 2016, Pages 21-23

  Konstam, Marvin A ^a   Upshaw, Jenica ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Healthcare outcomes; Healthcare quality; Predictive models

Indexed keywords

HEALTH STATUS; HEART FAILURE; HOSPITAL CARE; HOSPITAL READMISSION; HUMAN; INFORMATION SEEKING; MEDICATION COMPLIANCE; MORTALITY; NOTE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; SOCIAL PSYCHOLOGY; SOCIAL STATUS; HEALTH CARE QUALITY; TREATMENT OUTCOME;

HEART FAILURE; HUMANS; MEDICAL FUTILITY; PATIENT READMISSION; QUALITY OF HEALTH CARE;

EID: 84951862015     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2015.10.002     Document Type: Editorial

References (26)

1. Homer. The Odyssey. Book 11:593. Available at . Accessed November 6, 2015. http://www.poetryintranslation.com/PITBR/Greek/Odyssey11.htm.
2. Rau J. Medicare to penalize 2,217 hospitals for excess readmissions. Kaiser Health News August 13, 2012, Available at: http://khn.org/news/medicare-hospitals-readmissions-penalties. Accessed November 6, 2015.
3. Rau J. Medicare fines 2,610 hospitals in third round of readmission penalties. Kaiser Health News October 2, 2014, Available at: http://khn.org/news/medicare-readmissions-penalties-2015. Accessed November 6, 2015.
4. Krumholz H.M., Chaudhry S.I., Spertus J.A., Mattera J.A., Hodshon B., Herrin J. Do non-clinical factors improve prediction of readmission risk? Results from the Tele-HF study (Telemonitoring to Improve Heart Failure Outcomes). J Am Coll Cardiol HF 2016, 4:12-20.
5. Keenan P.S., Normand S.L., Lin Z., Drye E.E., Bhat K.R., Ross J.S., et al. An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure. Circ Cardiovasc Qual Outcomes 2008, 1:29-37.
6. Kansagara D., Englander H., Salanitro A., Kagen D., Theobald C., Freeman M., et al. Risk prediction models for hospital readmission: a systematic review. JAMA 2011, 306:1688-1698.
7. Ross J.S., Mulvey G.K., Stauffer B., Patlolla V., Bernheim S.M., Keenan P.S., et al. Statistical models and patient predictors of readmission for heart failure: a systematic review. Arch Intern Med 2008, 168:1371-1386.
8. Chaudhry S.I., Mattera J.A., Curtis J.P., Spertus J.A., Herrin J., Lin Z., et al. Telemonitoring in patients with heart failure. N Engl J Med 2010, 363:2301-2309.
9. Jencks S.F., Williams M.V., Coleman E.A. Rehospitalizations among patients in the Medicare fee-for-service program. N Engle J Med 2009, 360:1418-1428.
10. Konstam M.A. Heart failure in the lifetime of Musca domestica (the common housefly). J Am Coll Cardiol HF 2013, 1:178-180.
11. Bueno H., Ross J.S., Wang Y., Chen J., Vidan M.T., Normand S.L., et al. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. JAMA 2010, 303:2141-2147.
12. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302. SOLVD Investigators.
13. Granger C.B., McMurray J.J., Yusuf S., Held P., Michelson E.L., Olofsson B., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362:772-776.
14. Hjalmarson A., Goldstein S., Fagerberg B., Wedel H., Waagstein F., Kjekshus J., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000, 283:1295-1302.
15. Zannad F., McMurray J.J., Krum H., van Veldhuisen D.J., Swedberg K., Shi H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011, 364:11-21.
16. Cleland J.G., Daubert J.C., Erdmann E., Freemantle N., Gras D., Kappenberger L., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005, 352:1539-1549.
17. Gorodeski E.Z., Starling R.C., Blackstone E.H. Are all readmissions bad readmissions?. N Engl J Med 2010, 363:297-298.
18. Krumholz H.M., Lin Z., Keenan P.S., Chen J., Ross J.S., Drye E.E., et al. Relationship between hospital readmission and mortality rates for patients hospitalized with acute myocardial infarction, heart failure, or pneumonia. JAMA 2013, 309:587-593.
19. Putter H., Fiocco M., Geskus R.B. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007, 26:2389-2430.
20. Upshaw J.K., Huggins G.S., Noubary F., Kent D.M. A multi-state model to predict heart failure hospitalizations and all-cause mortality in outpatients with heart failure. J Card Fail 2015, 21:S113.
21. Kimmelstiel C., Levine D., Perry K., Patel A.R., Sadaniantz A., Gorham N., et al. Randomized, controlled evaluation of short- and long-term benefits of heart failure disease management within a diverse provider network: the SPAN-CHF trial. Circulation 2004, 110:1450-1455.
22. Weintraub A., Gregory D., Patel A.R., Levine D., Venesy D., Perry K., et al. A multicenter randomized controlled evaluation of automated home monitoring and telephonic disease management in patients recently hospitalized for congestive heart failure: the SPAN-CHF II trial. J Card Fail 2010, 16:285-292.
23. Krumholz H.M. Post-hospital syndrome-an acquired, transient condition of generalized risk. N Engl J Med 2013, 368:100-102.
24. Curtis L.H., Mi X., Qualls L.G., Check D.K., Hammill B.G., Hammill S.C., et al. Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. Am Heart J 2013, 165:979-986.e1.
25. Gattis W.A., O'Connor C.M. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure. Am J Card 2004, 93:74B-76B.
26. Hernandez A.F., Mi X., Hammill B.G., Hammill S.C., Heidenreich P.A., Masoudi F.A., et al. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. JAMA 2012, 308:2097-2107.